Beyond gene-disease validity: capturing structured data on inheritance, allelic-requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions

Analysis of inheritance and disease-associated variant consequences in genes implicated in inherited cardiac conditions

We analysed evidence to determine the inheritance pattern, allelic requirement, disease mechanism, and disease-relevant variant classes for 65 gene-disease pairs for major ICCs (Figure 1). We analysed genes classified with “Definitive” or “Strong” evidence by The Clinical Genome Resource(11) (ClinGen) Gene Curation Expert Panels (GCEPs) for seven CV diseases under a Mendelian (monogenic) model (accessed November 2020): Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Long QT Syndrome (LQTS), Brugada syndrome (BrS), Catecholaminergic polymorphic ventricular tachycardia (CPVT), and Short QT syndrome (SQTS)(12–17). Information on these ClinGen expert panels, membership, and curation activity can be found at www.clinicalgenome.org. For HCM, we included both genes causing typical HCM, and also genes associated with syndromic disorders where apparently isolated left ventricular hypertrophy (LVH) may be the presenting feature (genocopies)(16) Seven channelopathy gene-disease pairs classified by ClinGen as having “Moderate” strength of evidence for monogenic disease are included (CALM1-CPVT, CALM2-CPVT, CALM3-CPVT, CASQ2-CPVT, KCNE1-JLN, SLC4A3-SQTS, KCNJ2-SQTS), following discussion with the channelopathy expert review panel for this project, and where there was sufficient data to adjudicate the required fields. SLC22A5 was also evaluated as a phenotypic mimic of SQTS: although it is classified as “Disputed” by ClinGen Short QT GCEP in relation to true SQTS, it is definitively associated with systemic primary carnitine deficiency disease, which can present similarly to SQTS and might reasonably be included in gene panels for diagnostic assessment of patients presenting with this phenotype. See Table 1, Table 2 and Additional File 1 for a complete list of the gene-disease pairs evaluated.

• Download figure
• Open in new tab

Figure 1:

Flow chart depicting the analysis of inheritance and disease mechanism in established inherited cardiac genes. A structured representation of the resulting data is available in the Additional Materials, and also through G2P (https://www.ebi.ac.uk/gene2phenotype/downloads), which is also searchable through the GenCC portal (https://thegencc.org/). ARVC – arrhythmogenic right ventricular cardiomyopathy, BrS – Brugada syndrome, CPVT – catecholaminergic polymorphic ventricular tachycardia, DCM – dilated cardiomyopathy, G2P – gene2phenotype, GenCC – Gene Curation Coalition, HCM – hypertrophic cardiomyopathy, LQTS – long QT syndrome, SQTS – short QT syndrome.

Inheritance, allelic requirement, and disease-associated variant consequences (as a proxy for disease mechanism), are described using previously agreed standardised terms developed by the GenCC (https://thegencc.org/)(7). These terms are formalised in the sequence ontology (SO) (http://www.sequenceontology.org) and human phenotype ontology (HPO) (https://hpo.jax.org/app/). Briefly, since the precise disease mechanism is not always known, six high-level variant-consequence terms are used to describe disease-associated variant consequences. These are assigned depending on which variant classes are associated with disease (see Tables 2 and 3 in Roberts AM et al(7)). As examples, “decreased gene product level” [SO:0002316] is used when disease is caused by variants that decrease the level or amount of gene product produced (e.g. variants leading to premature termination codons (PTCs) that trigger nonsense mediated decay (NMD), and gene deletions) and “altered gene product sequence” [SO:0002318] is used for non-truncating variants that instead alter the sequence of the gene product such as the amino acid sequence of a protein (e.g. missense variants, inframe insertions or deletions (indels), PTCs predicted to escape NMD, and stop loss). Variants producing PTCs are often referred to as “loss of function (LoF)” variants, but a PTC could lead to LoF, gain of function (GoF) through loss of a terminal regulatory region, or dominant negative effect. Similarly missense variants can cause GoF, LoF, or dominant negative effects. Using known pathogenic variant classes to describe which consequences, at a sequence level, have been associated with disease allows prediction of which other variant classes may be pathogenic whilst recognising that the downstream mechanisms following a particular sequence consequence can be diverse(7). More than one disease-associated variant consequence term can be used for each gene-disease pair.

Evidence was collected primarily from published, peer-reviewed literature, but also publicly accessible resources such as ClinGen and variant databases (e.g., ClinVar). Building on the previous work by ClinGen GCEPs to determine gene-disease validity, each gene-disease pair was analysed by an individual curator following a standard operating procedure for determining inheritance and disease-associated variant consequences (see Additional File 2). Curation results were then reviewed by panels of international experts (clinicians and scientists) drawn from the relevant disease area.

Development of CardiacG2P

A structured representation of the resulting data is available in the Additional Materials, and also through G2P (https://www.ebi.ac.uk/gene2phenotype/downloads), which is also searchable through the GenCC portal (https://thegencc.org/).

For each curation entry, a gene or locus is linked to a disease via a disease associated variant consequence (as a proxy for disease mechanism) and allelic requirement. Additional information including a confidence category of gene-disease validity (as previously assigned by ClinGen), a narrative summary describing key messages from the expert review, and relevant publication identifiers is also stored.

Unless specifically mentioned, genes previously curated for validity by ClinGen, but not classified as “Definitive” or “Strong” for cardiac disease are included on the panel for completeness. The panel reports the gene-disease validity classification (e.g., “Limited” evidence), but does not speculate on inheritance and mechanism terms where the gene- disease relationship is not established (for information on the current version of the ClinGen gene-disease validity SOP see: https://clinicalgenome.org/curation-activities/gene-disease-validity/training-materials/).

Validating CardiacG2P

We evaluated the utility of CardiacG2P by comparing a variant prioritisation pipeline incorporating data from this structured resource against two alternative generic approaches available to an analyst without disease-specific expertise (see Figure 2). All three pipelines interrogate the same gene list which includes the 21 HCM and 12 DCM genes evaluated here.

• ● Pipeline 1: Generic bioinformatics analysis pipeline with 3-step filtering approach: filtering on gene symbol (for 33 gene-disease relationships classified by ClinGen as “Strong” or “Definitive” for HCM and/or DCM), retaining only rare variants (gnomAD(18) global allele frequency <0.0001), retaining only protein altering variants (PAVs).

• ● Pipeline 2: Generic bioinformatics analysis pipeline with 4-step filtering approach: on gene symbol, retaining only rare variants (gnomAD global allele frequency <0.0001), retaining variants that are either high impact (i.e. protein truncating variants (e.g. stop gained, frameshift) AND predicted to result in loss of function with high confidence by LOFTEE(18), a VEP plugin), OR that are previously classified in ClinVar as P/LP (as annotated by VEP).

• ● Pipeline 3 (Cardiac G2P): Using CardiacG2P dataset, variants were filtered: on gene symbol, retaining only rare variants (gnomAD global allele frequency <0.0001), and with allelic requirement, variant consequence, and gene specific annotations of a restricted repertoire of pathogenic alleles all appropriate for the disease under interrogation – e.g. restricted variant classes, specific variants, or restricted regions of the protein.

• Download figure
• Open in new tab

Figure 2:

Validating CardiacG2P. Two generic variant prioritisation pipelines (pipeline 1 &2) were compared to CardiacG2P (pipeline 3). All 3 pipelines interrogate the same gene list which includes 21 HCM and 12 DCM genes. Pipeline 1: filtered rare (gnomAD global allele frequency (AF) <0.0001) AND protein altering variants. Pipeline 2: filtered rare (AF <0.0001) AND ((high impact variants (e.g. stop gained, frameshift) AND high confidence by LOFTEE (VEP plugin) LoF variants) OR ClinVar P/LP variants). CardiacG2P (pipeline 3): filtered rare variants (AF <0.0001) and incorporates allelic requirement, variant consequence and gene specific annotations of a restricted repertoire of pathogenic alleles appropriate for the disease under interrogation – e.g. restricted variant classes, specific variants, or restricted regions of the protein. Set 1: contains 286 unique variants identified and classified as P/LP for HCM or DCM by a specialist NHS cardiovascular genetics lab. A VCF file with these variants was created, annotated by VEP and filtered according to the 3 pipelines. Sensitivity (number of P/LP variants retained) was assessed. Set 2a: is a merged VCF file with SNVs and indels from 200 patients with HCM or DCM. Set2b: is a merged VCF file with SNVs and indels from 200 healthy volunteers. Set2a and 2b were separately annotated by VEP and filtered according to the 3 pipelines. Positive rate (the number of variants retained for further analysis) was assessed. AF – allele frequency, DCM – dilated cardiomyopathy, HCM – hypertrophic cardiomyopathy, indels – insertion or deletion variants, LoF – loss of function, P/LP – pathogenic/likely pathogenic, SNVs – single nucleotide variants, VCF – variant call format, VEP – variant effect predictor

To compare these different approaches, two test sets of data were generated (see Figure 2).

Set 1: to assess sensitivity

Set 1 contains 286 unique gold-standard true positive variants classified as P/LP for HCM and DCM in the last 3 years by the Clinical Genetics & Genomics Laboratory of the NHS Genomic Medicine Service South East Genomics Laboratory Hub at the Royal Brompton Hospital, London, which is one of 4 NHS England specialist cardiovascular genetics labs. These variants were identified using a custom gene panel using Agilent SureSelect QXT library preparation sequenced on Illumina MiSeq or NextSeq platforms. All variants were evaluated following guidelines produced by the ACMG/AMP(19) and the Association for Clinical Genomic Science (ACGS)(20)using an in-house validated pipeline.

For this study, a variant call format (VCF) file was created using these variants, and then annotated using VEP(9) version 104 and filtered according to the 3 pipelines. We compared the number of P/LP variants retained by each of the 3 methods.

Set 2: to assess the positive rate - the number of variants retained for further analysis

Set 2a contains data from 200 patients with cardiomyopathy (either HCM or DCM) from the Royal Brompton & Harefield Hospitals Cardiovascular Research Biobank. Set 2b contains data from 200 healthy volunteers recruited for the digital heart project(21). Participants provided written informed consent, and research had ethics committee approval. No individual patient data is reported. The GRCh37 reference genome assembly was used for sequencing and analysis. Details of the sequencing panels and platforms and the bioinformatics pipelines used for variant calling are previously reported(22). Briefly, samples were sequenced using the Illumina TruSight Cardio Sequencing Kit, which includes 174 genes reported as associated with ICCs, on the Illumina MiSeq and NextSeq platforms. Targeted DNA libraries were prepared according to manufacturers’ protocols before performing paired-end sequencing. For this study, merged VCF files containing single nucleotide variants (SNVs), and insertion or deletion variants were annotated using VEP version 104 and filtered according to the 3 pipelines described above.

Since it is not possible to define a gold-standard classification for these variants that does not incorporate the same expert knowledge captured in CardiacG2P (except potentially for a very small number of variants with orthogonal segregation data), we report the total number of variants retained by each of the three methods (the positive rate), rather than positive predictive value. This is indicative of the analytical burden for a diagnostic laboratory manually interpreting variants of interest retained by a filtering pipeline. We have included a healthy cohort to represent the potential analytical burden of secondary findings.

Inheritance and disease-associated variant consequences in established ICC genes

Forty cardiomyopathy gene-disease pairs (22 for HCM, 12 for DCM and 6 for ARVC; overall 33 unique genes) were analysed for inheritance pattern, allelic requirement, disease-associated variant consequences, and variant classes reported with evidence of pathogenicity. These are presented in Table 1 (typical HCM, DCM and ARVC) and Additional File 1 (syndromic disorders that include HCM where LVH may be a presenting feature). Twenty-five channelopathy gene- disease pairs (11 for LQTS, 1 for BrS, 8 for CPVT and 5 for SQTS; overall 15 unique genes) are presented in Table 2. Narrative summaries accompany each gene-disease pair, with content including relevant transcripts, specific pathogenic variants, mutational hotspots, phenotype notes and other important information raised during the expert panel reviews and discussion (see Additional File 3 or Additional File 4).

Cardiomyopathy

Cardiomyopathy genes are predominately characterised by autosomal dominant inheritance with incomplete penetrance. However, 3/6 ARVC genes demonstrate both autosomal dominant and recessive inheritance; JUP-related Naxos disease (a syndrome characterised by ARVC, woolly hair and palmoplantar keratoderma) is exclusively inherited in an autosomal recessive manner, and 3/14 syndromic HCM genes (FHL1, GLA and LAMP2) are X-linked.

Importantly, only one of the eight core sarcomere-encoding HCM-associated genes (MYBPC3) causes disease through haploinsufficiency. LoF is not an established mechanism for the other 7 core HCM genes (as listed in Table 1) and NMD-competent PTCs are not known to be pathogenic. Instead, missense variants and variants predicted to escape NMD leading to an altered gene product sequence rather than decreased gene product level should be prioritised. This is also the case for 8/14 syndromic HCM gene-disease pairs (CACNA1C, FLNC, PRKAG2, PTPN11 (Noonan), PTPN11 (Noonan syndrome with multiple lentigines), RAF1, RIT1, TTR), 3/12 DCM (DES, TNNC1 and TNNT2) and 2/6 ARVC (JUP, TMEM43).

Additional useful information for variant filtering is captured in individual narrative summaries. For example, for TTN-related DCM, only PTCs that are in exons constitutively expressed in both major adult cardiac isoforms (PSI > 0.9) should be prioritised (21,23,24).

Very few pathogenic missense variants in TTN-related DCM have been identified: to our knowledge there are only three reported with segregation evidence(25–27). Individually rare missense variants in TTN are collectively extremely common in the population (>50%, depending on allele frequency cut-off), and there are seldom established approaches to prioritise these in the absence of an informative pedigree. There are instances where evidence for disease comes primarily from one variant class such as missense variants only in MYL2, MYL3 and TPM1-related HCM, or from a single well-characterised variant, such as TMEM43-related ARVC and the founder missense variant NM_024334.3(TMEM43) c.1073C>T (p.S358L)(28). Pathogenicity of other variant classes, or indeed other missense variants, for TMEM43 is not established and this should guide interpretation of variants in these gene- disease relationships.

For some gene-disease relationships, there are gene regions where there is a high confidence for pathogenicity, for example exon 9 in RBM20 related DCM (RS motif, amino acids 634-638). Other examples of mutational hotspots are referenced in individual curations.

Channelopathy

The channelopathy genes are predominately characterised by autosomal dominant inheritance, though 7/25 gene-disease pairs demonstrate autosomal recessive inheritance. For 7/11 LQTS, 4/7 CPVT and 5/5 SQTS, disease is due to altered gene product sequence and not a decrease in gene product level. For these gene-disease relationships, it is missense variants and other non-truncating variants that should be prioritised and assessed for pathogenicity.

Many of the channelopathy genes are implicated in more than one phenotype, or overlapping phenotypes; 25 gene-disease relationships are evaluated here but only 15 unique genes. Importantly, for several genes distinct variant classes drive different phenotypes through distinct mechanisms. As an example, both PTCs and missense variants leading to LoF of KCNQ1 are associated with LQTS and Jervell Lange-Nielsen syndrome. In contrast, almost all evidence for KCNQ1 as a cause of SQTS is derived from a single missense variant (p.V141M) and functional studies in cell models have confirmed GoF as the mechanism (29,30). Similarly, both PTCs and non-truncating variants leading to LoF of SCN5A are associated with BrS, whereas SCN5A-related LQTS is caused by pathogenic missense variants and inframe indels leading to GoF.

For certain gene-disease pairs, there are gene regions where there is a higher confidence for pathogenicity such as, for non-truncating variants, the transmembrane regions and C- terminus domains for KCNQ1-related LQTS (31,32), and the ion channel transmembrane regions and specific N-terminus and C-terminus domains for KCNH2-related LQTS(32). There are other examples of mutational hotspots referenced in individual curations (see Additional File 3 or Additional File 4) .

CardiacG2P reduces the number of variants prioritised, without compromising sensitivity to detect true positives

1. Assessing sensitivity

We assessed variant filtering using the CardiacG2P dataset for the identification of known P/LP variants previously classified by the cardiovascular laboratory of the NHS Genomic Medicine Service South East Genomics Laboratory Hub at the Royal Brompton Hospital, London. A total of 286 P/LP variants in 16 HCM/DCM genes were used to assess the performance of CardiacG2P compared to two other generic pipelines (see Figure 3A). CardiacG2P correctly identified 282/286 variants, a sensitivity of 98.6%. This was superior to both alternative approaches (pipeline 1 272/286, sensitivity 95.1%, P_fisher=0.028; pipeline 2 199/286, 69.6%, P_fisher=1.8x10^-24). Four variants were not retained by CardiacG2P. These comprised 1 TTN missense variant and 2 intronic and 1 synonymous variant in LMNA. All four of these variants were classified as P/LP by the clinical laboratory due to impacts on splicing, so the limited sensitivity is due to an incomplete upstream annotation of the variant consequence, rather than an “error” in downstream filtering.

• Download figure
• Open in new tab

Figure 3:

A variant prioritisation approach that incorporates structured data representing disease mechanisms and allelic requirement for specific gene-disease pairs (CardiacG2P) outperforms other scalable variant-prioritisation approaches. A – comparison of the sensitivity of 3 variant filtering approaches to prioritise 286 variants classified as pathogenic/likely pathogenic (P/LP) for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Error bars = 95% confidence intervals (CI). Pipeline 1 (green), prioritises all rare protein altering variants (PAV), sensitivity 0.95, 95% CI [0.92, 0.97]; Pipeline 2 (red), prioritises all rare loss of function (LoF) variants, and those classified as P/LP by ClinVar, sensitivity 0.70, 95% CI [0.64, 0.75]; Pipeline 3 (purple), prioritises variant classes according to specific characteristics of each gene-disease pair (CardiacG2P), sensitivity 0.99, 95% CI [0.96, 1.0]. CardiacG2P has a higher sensitivity when compared to Pipeline 1, P^fisher = 0.028 and Pipeline 2, P^fisher = 1.8x10^-24. B – the positive rate (number of variants retained) by 3 variant filtering approaches for a cardiomyopathy cases (left panel), using a dataset of 5681 unique variants from 200 individuals with confirmed HCM/DCM, and healthy controls (right panel), using a dataset of 6060 unique variants from 200 healthy individuals. Pipeline 1 (green), filtering for rare PAV; Pipeline 2 (red), filtering for rare LoF variants or those classified as P/LP by ClinVar; Pipeline 3 (purple), filtering using CardiacG2P. CardiacG2P demonstrated more efficient variant prioritisation compared to Pipeline 1 in both the disease cohort (P^fisher = 0.002) and healthy controls (P^fisher = <0.0001).

Ethics approval and consent to participate

No individual patient data is reported.

Royal Brompton & Harefield Hospitals Cardiovascular Research Biobank participants provided written informed consent, HRA research ethics approval: South Central Hampshire B Research Ethics Committee 19/SC/0257. Healthy volunteers in the digital heart project provided written informed consent, HRA research ethics committee approval: London – West London and GTAC Research Ethics Committee 09/H0707/69.

Consent for publication

Not applicable

Availability of data and materials

All data generated during this study are included in this published article. A structured representation of the data is available in the Additional Materials, and also through G2P (https://www.ebi.ac.uk/gene2phenotype/downloads), which is also searchable through the GenCC portal (https://thegencc.org/).

Competing interests

EMM is a Consultant for Amgen, AstraZeneca, Avidity Biosciences, Cytokinetics, PepGen, Pfizer, Stealth Biotherapeutics, Tenaya Therapeutics, and founder of Ikaika Therapeutics. CJ is a Consultant for Pfizer Inc (paid), StrideBio Inc (unpaid), and Tenaya Inc (unpaid). TL has research grant support from Pfizer. DPJ is a Consultant for Alexion, Alleviant, Cytokinetics, Novo Nordisk, Pfizer, and Tenaya Therapeutics. JI has research grant support from Bristol Myers Squibb. J.S.W. has received research support or consultancy fees from Myokardia, Bristol-Myers Squibb, Pfizer, and Foresite Labs. No other authors report competing interests.

Funding

J.S.W was supported by the Sir Jules Thorn Trust [21JTA], Wellcome Trust [107469/Z/15/Z], Medical Research Council (UK), British Heart Foundation [RE/18/4/34215]; NHLI Foundation Royston Centre for Cardiomyopathy Research, and the NIHR Imperial College Biomedical Research Centre. KSJ was supported by the Wellcome Trust [222883/Z/21/Z]. AMR was supported by the British Heart Foundation Fellowship [FS/CRLF/21/23011]. PT was supported by the Wellcome Trust [200990/A/16/Z].This publication was supported in part by the National Human Genome Research Institute of the National Institutes of Health through the following grants: U24HG009650. AW and PvT are supported by CVON/Dutch Heart Foundation PREDICT2 (2018–30); RT is supported by the Canada Research Chairs program; TL receives support from BHF Research Accelerator; BC is a Senior Clinical Investigator of the Research Foundation – Flanders; EMM is supported by NIH HL128075, American Heart Association.

For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

The views expressed in this work are those of the authors and not necessarily those of the funders.

Authors’ contributions

JSW, AMR, KSJ conceived the work. RW, PJO, ME, AF, MG, KSJ curated gene-disease pairs and presented these to the expert panels for review. EO, APL, EMM, C.AAC, LB, OJ, BC, CJ, SP, TL, ME, DPJ, PvT, EJ, BA, REH, NK, CT, JI reviewed cardiomyopathy curations; JR, MC, WZ, AA, ACS, RT, VN, AW, MG reviewed channelopathy curations; JSW, PT, KSJ conceived the design for validating CardiacG2P experiment; PT performed the analysis for validating CardiacG2P; Manuscript written by KSJ, JSW, AMR; all authors read and approved the final manuscript.